Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Stock Has Average Target Price of $18.25 According to Analysts

Unicycive Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Analyst opinion is moderately positive: Seven analysts give Unicycive a consensus “Moderate Buy” rating, with five buys, one hold and one sell. The average 12-month price target is $18.25.
  • Shares are trading near their 52-week low: UNCY opened at $3.35, compared with a 52-week range of $3.33–$8.74. Recent analyst actions were mixed, including price-target cuts from Guggenheim and HC Wainwright.
  • The company remains loss-making: Unicycive reported a quarterly loss of $0.25 per share, better than analysts’ expected $0.35 loss; analysts project a full-year loss of $1.05 per share.
  • Five stocks to consider instead of Unicycive Therapeutics.

Shares of Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Get Free Report) have been given an average recommendation of "Moderate Buy" by the seven analysts that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $18.25.

UNCY has been the topic of several research analyst reports. Wall Street Zen cut shares of Unicycive Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, November 14th. Zacks Research upgraded shares of Unicycive Therapeutics from a "strong sell" rating to a "hold" rating in a report on Wednesday, August 19th. Weiss Ratings restated a "sell (d-)" rating on shares of Unicycive Therapeutics in a report on Friday, September 4th. Guggenheim reaffirmed a "buy" rating and issued a $25.00 price objective (down from $37.00) on shares of Unicycive Therapeutics in a report on Thursday, August 13th. Finally, HC Wainwright dropped their price objective on shares of Unicycive Therapeutics from $15.00 to $13.00 and set a "buy" rating for the company in a report on Tuesday, September 29th.

Read Our Latest Stock Report on UNCY

Unicycive Therapeutics Price Performance

Unicycive Therapeutics stock opened at $3.35 on Friday. The firm has a fifty day moving average price of $4.03 and a two-hundred day moving average price of $5.86. Unicycive Therapeutics has a fifty-two week low of $3.33 and a fifty-two week high of $8.74. The firm has a market cap of $93.30 million, a price-to-earnings ratio of -2.01 and a beta of 1.91.

Unicycive Therapeutics (NASDAQ:UNCY - Get Free Report) last released its earnings results on Monday, November 16th. The company reported ($0.25) earnings per share for the quarter, topping analysts' consensus estimates of ($0.35) by $0.10. As a group, sell-side analysts expect that Unicycive Therapeutics will post -1.05 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of UNCY. Pinnacle Wealth Planning Services Inc. bought a new position in shares of Unicycive Therapeutics during the 3rd quarter valued at approximately $36,000. Chicago Partners Investment Group LLC boosted its position in shares of Unicycive Therapeutics by 26.0% in the third quarter. Chicago Partners Investment Group LLC now owns 26,966 shares of the company's stock worth $105,000 after purchasing an additional 5,556 shares during the period. Renaissance Technologies LLC bought a new position in shares of Unicycive Therapeutics in the first quarter worth approximately $161,000. Bank of America Corp DE increased its stake in Unicycive Therapeutics by 19,327.6% in the 1st quarter. Bank of America Corp DE now owns 29,530 shares of the company's stock worth $194,000 after buying an additional 29,378 shares in the last quarter. Finally, Bank of New York Mellon Corp purchased a new stake in Unicycive Therapeutics in the 2nd quarter worth $248,000. Hedge funds and other institutional investors own 40.42% of the company's stock.

Unicycive Therapeutics News Summary

Here's some of the latest news about UNCY:

  • Positive Sentiment: HC Wainwright raised several 2026–27 EPS estimates, kept its Buy rating, and reiterated a $13 price target—potential support for the stock. HC Wainwright forecast article
  • Negative Sentiment: A report said Unicycive’s third-quarter loss widened to $7.0 million, highlighting ongoing losses. Article on Unicycive’s Q3 loss
  • Negative Sentiment: Despite raising near-term estimates, HC Wainwright cut its 2028–30 EPS forecasts substantially. Noble Financial also lowered its 2026 estimates, adding a more cautious note to the outlook. Analyst estimate reports

About Unicycive Therapeutics

(Get Free Report)

Unicycive Therapeutics is a biopharmaceutical company focused on developing treatments for kidney diseases. Its lead program, oxylanthanum carbonate (OLC), is an oral phosphate binder being developed to help manage hyperphosphatemia, or elevated blood phosphate levels, in people with chronic kidney disease, including patients receiving dialysis. The company is also developing UNI-494, an investigational small-molecule therapy for acute kidney injury. These programs reflect Unicycive's focus on conditions for which treatment options may be limited.

Further Reading

Analyst Recommendations for Unicycive Therapeutics (NASDAQ:UNCY)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Unicycive Therapeutics Right Now?

Before you consider Unicycive Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Unicycive Therapeutics wasn't on the list.

While Unicycive Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines